Related Content

Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. (Pghoto by Dave Fornell)
Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor
News | Stents Bioresorbable | October 12, 2018
October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom
News | Stents Bioresorbable | November 07, 2016
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3 in Washington, D.C...
News | June 05, 2015
REVA Medical Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its Fantom...
News | February 12, 2015
A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University...
News | December 31, 2014
Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold.
Feature | Stents Bioresorbable | September 03, 2014 | Dave Fornell
A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and...
News | January 23, 2014
An implant of the ReZolve2 bioresorbable...
News | April 02, 2013
Reva Medical Inc. announced that it has initiated patient enrollment with its ReZolve2 bioresorbable sirolimus-eluting...
News | July 16, 2012
July 16, 2012 — Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting...